![]() Alnylam Alnylam is a biopharmaceutical company that develops ribonucleic acid interference (RNAi) therapeutics for hepatic porphyria, primary hyperoxaluria type 1 (PH1), cardiovascular, and polyneuropathy treatments. | ![]() Reata Pharmaceuticals Reata Pharmaceuticals is a biopharmaceutical company that develops therapeutics for patients with serious or life-threatening diseases. | ![]() Moderna Moderna (formerly Moderna Therapeutics) is a biotechnology company focused on messenger RNA (mRNA) medicine. | |
Founding Date | Founding Date 2002 | Founding Date 2002 | Founding Date 2010 |
Type | Type Public | Type Public | Type Public |
Tags | |||
Locations | Locations Plano, US HQ Irving, US Plano, US | ||
Employees | Employees 1,32324% increase | Employees 3217% decrease | Employees 5,60044% increase |
Valuation ($) | Valuation ($) 36.5 b | Valuation ($) 6.6 b | Valuation ($) 21.2 b |
Financial | |||
Revenue (est.) | Revenue (est.) $1.8b (FY, 2023) | Revenue (est.) $2.2m (FY, 2022) | Revenue (est.) $6.8b (FY, 2023) |
Cost of goods | Cost of goods $268.2m (FY, 2023) | Cost of goods N/A | Cost of goods $4.7b (FY, 2023) |
Gross profit | Gross profit $1.6b (FY, 2023) | Gross profit N/A | Gross profit $2.2b (FY, 2023) |
Net income | Net income ($440.2m) (FY, 2023) | Net income ($311.9m) (FY, 2022) | Net income ($4.7b) (FY, 2023) |
Operating ⚠ | |||
Patents Issued | Patents Issued N/A | Patents Issued 240 (FY, 2016) | Patents Issued 270 (FY, 2020) |
Funding | |||
Total funding raised | Total funding raised $ 1.5b | Total funding raised $ 468.9m | Total funding raised $ 1.8b |
Reata Pharmaceuticals is a biopharmaceutical company that develops therapeutics for patients with serious or life-threatening diseases.
View companyModerna (formerly Moderna Therapeutics) is a biotechnology company focused on messenger RNA (mRNA) medicine.
View company